VivoSeq
Oncology

Neuroendocrine Tumor

3

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Neuroendocrine Tumor is an early-stage landscape with 3 programs across 1 company. The most active players are Novartis. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

25/100

Attrition Rate

35/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSRadiopharmaceutical133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

17

clinical trials

Terminated3 · 18%
Active, not recruiting3 · 18%
Withdrawn3 · 18%
Unknown status3 · 18%
Recruiting3 · 18%
Completed2 · 12%

Clinical Trials

Trial Activity

17 trials

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Recruiting·—·Phase 2/3·NCT05749289·400 enrolled
Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
Recruiting·IInstitut Claudius Regaud·Preclinical·NCT06876532·150 enrolled
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Recruiting·VVanderbilt-Ingram Cancer Center·Approved·NCT06016855·6 enrolled
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT00569127·427 enrolled
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Active, not recruiting·OOrano Med LLC·Phase 2·NCT05153772·69 enrolled
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT01841736·171 enrolled
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor
Completed·UUniversity Hospital, Toulouse·N/A·NCT03667092·47 enrolled
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Completed·—·Phase 1·NCT03197012·10 enrolled
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
Terminated·—·Phase 1·NCT03724409·3 enrolled
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Terminated·EErasmus Medical Center·Phase 2·NCT07012330·111 enrolled
Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
Terminated·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT02465112·4 enrolled
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Withdrawn·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02831179
Pasireotide Treatment for Neuroendocrine Tumor
Withdrawn·UUniversity of Maryland, Baltimore·Phase 4·NCT02779257
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Withdrawn·—·Phase 2·NCT00003514
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Unknown status·PPeking Union Medical College Hospital·Phase 1·NCT04041882·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)